Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® | MicrobiomeTrials← Back to trialsNCT06298409
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-02-15Est. Completion: 2026-02-28
Enrollment target: 34 participants Locations- Silicon Valley Gastroenterology, Mountain View, California, United States
Other microbiome trials you might be interested in
Irritable Bowel Syndrome (IBS)Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal ba…
Baltimore, United StatesEst. completion Dec 31, 2027
Food Intolerance SyndromesSmall Intestinal Bacterial Overgrowth Syndrome (SIBO)Breath Tests
Hydrogen (H₂) breath tests serve several purposes. (i) detect malabsorption of carbohydrates such as lactose and fructos…
Arlesheim, SwitzerlandCompleted Dec 31, 2025
Small Intestine Bacterial Overgrowth
The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacter…
Dhaka, BangladeshEst. completion Nov 2, 2026